- BioVaxys Technology Corp. (BVAXF, Financial) and SpayVac for Wildlife expand license agreement to include commercial aquaculture and farm-raised fish markets.
- The expanded market targets a significant opportunity in farm-raised Atlantic salmon and rainbow trout, with an annual harvest reaching approximately 3.28 million metric tons.
- SpayVac's single-dose fertility-control vaccines offer a cost-effective solution with a 4-10 year efficacy, advancing to the second phase of development in aquaculture trials.
BioVaxys Technology Corp. (BVAXF) and SpayVac for Wildlife have broadened their License Agreement to integrate commercial aquaculture and farm-raised fish markets. This strategic move targets the lucrative market of farm-raised Atlantic salmon and rainbow trout, which boasts an annual yield of about 3.28 million metric tons, translating to an impressive 800 million individual fish.
SpayVac's innovative single-dose fertility-control vaccines present a viable alternative to the genetic manipulation technique of triploidy, commonly used in aquaculture to ensure sterility. Initial proof-of-concept trials have demonstrably progressed to the second phase, focusing efforts on refining the injection timing within the fish's lifecycle. The vaccine employs a patented liposome-based delivery platform, courtesy of BioVaxys, renowned for its long-lasting contraceptive efficacy of 4-10 years across multiple species.
The expansion also paves the way for SpayVac to pursue regulatory approval for its vaccine applications in feral horses and free-ranging deer populations. The U.S. Bureau of Land Management (BLM) stands as a potential primary client, entrusted with managing more than 53,797 feral horses, a number significantly exceeding the designated Appropriate Management Level of 22,637. The BLM dedicates a substantial portion of its $153 million budget (66%) to the long-term management of these populations, highlighting a promising revenue stream for SpayVac.
